Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-01-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2014年限制性股票激励计划之限制性股票第一次解锁暨上市公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the unlocking and listing of restricted shares under a 2014 stock incentive plan by the company. It details the approval and implementation of the stock incentive plan, the conditions met for unlocking the shares, the number of shares unlocked, and the legal opinions related to the unlocking. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on the stock incentive plan execution and related share unlocking event. The document length is 4139 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about stock incentive unlocking and share listing, not a full report or financial statement.
2016-01-29 Chinese
关于董事、高级管理人员买入公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the purchase of company shares by directors and senior management personnel. It details the number of shares bought, the prices, and includes commitments by these individuals not to reduce their holdings within a year. The document references compliance with relevant laws and regulations concerning insider share transactions. There is no financial report, earnings data, or meeting materials. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on insider share purchases, confirming the classification as DIRS.
2016-01-29 Chinese
非公开发行限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares from a non-public issuance by the company 中源协和细胞基因工程股份有限公司. It details the number of shares becoming tradable, the lock-up periods, shareholder commitments, and changes in share capital structure. It references regulatory approvals and includes a verification opinion from an independent financial advisor. The document is not a full financial report, audit, or earnings release, but rather a formal announcement about share circulation and capital changes related to restricted shares becoming tradable. This fits the category of Share Issue/Capital Change (SHA), as it concerns the unlocking and listing of restricted shares and changes in share capital structure.
2016-01-27 Chinese
华英证券有限责任公司关于公司发行股份及支付现金购买资产并募集配套资金限售股份上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent service advisor's opinion regarding the unlocking and circulation of restricted shares related to a non-public issuance of shares for asset purchase and fundraising by Zhongyuan He and Cell Gene Engineering Co., Ltd. It includes regulatory references to the China Securities Regulatory Commission (CSRC) approvals, shareholding structure changes, lock-up periods, and compliance with securities laws and stock exchange rules. The document is not a full annual or interim financial report, nor is it a simple announcement. It is a formal audit or review opinion on a specific regulatory matter concerning share circulation and compliance, which fits the definition of an Audit Report / Information (AR). The document length is 3202 characters, which is relatively short but contains substantive content beyond a mere announcement or certification. Therefore, it is classified as AR with high confidence. FY 2015
2016-01-27 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 中源协和细胞基因工程股份有限公司 regarding an external investment in 天津百乐思生物科技发展有限公司. It details the investment amount, the investment agreement, board approval, shareholding structure changes, governance changes, performance commitments, and risk disclosures. The document is a formal announcement of a capital investment transaction and related agreements, not a financial report or earnings release. It does not contain financial statements or quarterly/yearly financial results. It is not a regulatory filing or a report publication announcement since it provides detailed transaction information. The content fits best under Capital/Financing Update (CAP) as it concerns a significant investment and capital structure change.
2016-01-25 Chinese
2016年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2016 first extraordinary shareholders' meeting of the company. It details the meeting date, attendance, voting results on specific proposals, and legal verification by lawyers. There is no financial data or report content, but rather an official announcement of the meeting's resolutions and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, not a full report or presentation.
2016-01-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.